These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
348 related articles for article (PubMed ID: 30762312)
1. Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancer. Shibaki R; Murakami S; Shinno Y; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Motoi N; Yamamoto N; Ohe Y Thorac Cancer; 2019 Apr; 10(4):815-822. PubMed ID: 30762312 [TBL] [Abstract][Full Text] [Related]
2. Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC. Takeyasu Y; Yoshida T; Shibaki R; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Yamamoto N; Motoi N; Ohe Y Clin Lung Cancer; 2021 Mar; 22(2):127-133.e3. PubMed ID: 33183972 [TBL] [Abstract][Full Text] [Related]
3. Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease. Shibaki R; Murakami S; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Motoi N; Kusumoto M; Yamamoto N; Ohe Y Med Oncol; 2019 Apr; 36(6):49. PubMed ID: 31030326 [TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis. Almutairi AR; Alkhatib N; Martin J; Babiker HM; Garland LL; McBride A; Abraham I Crit Rev Oncol Hematol; 2019 Oct; 142():16-25. PubMed ID: 31326706 [TBL] [Abstract][Full Text] [Related]
5. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1? Zhang Y; Zhou H; Zhang L J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312 [TBL] [Abstract][Full Text] [Related]
6. Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study. Lang D; Huemer F; Rinnerthaler G; Horner A; Wass R; Brehm E; Akbari K; Granitz M; Hutarew G; Kaiser B; Greil R; Lamprecht B Target Oncol; 2019 Dec; 14(6):707-717. PubMed ID: 31654203 [TBL] [Abstract][Full Text] [Related]
7. Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples. Zou Y; Xu L; Tang Q; You Q; Wang X; Ding W; Zhao J; Ren G BMC Cancer; 2020 Apr; 20(1):344. PubMed ID: 32321471 [TBL] [Abstract][Full Text] [Related]
8. First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy. Zhou Y; Lin Z; Zhang X; Chen C; Zhao H; Hong S; Zhang L J Immunother Cancer; 2019 May; 7(1):120. PubMed ID: 31053172 [TBL] [Abstract][Full Text] [Related]
9. Role of pleural and peritoneal metastasis in immune checkpoint inhibitors efficacy patients with non-small cell lung cancer: real-world data from a large cohort in France. Aarnink A; Fumet JD; Favier L; Truntzer C; Ghiringhelli F J Cancer Res Clin Oncol; 2020 Oct; 146(10):2699-2707. PubMed ID: 32474752 [TBL] [Abstract][Full Text] [Related]
10. Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study. Kawachi H; Tamiya M; Tamiya A; Ishii S; Hirano K; Matsumoto H; Fukuda Y; Yokoyama T; Kominami R; Fujimoto D; Hosoya K; Suzuki H; Hirashima T; Kanazu M; Sawa N; Uchida J; Morita M; Makio T; Hara S; Kumagai T Invest New Drugs; 2020 Feb; 38(1):211-218. PubMed ID: 31784866 [TBL] [Abstract][Full Text] [Related]
11. Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Non-Small-Cell Lung Cancer and High PD-L1 Tumor Expression. Tambo Y; Sone T; Shibata K; Nishi K; Shirasaki H; Yoneda T; Araya T; Kase K; Nishikawa S; Kimura H; Kasahara K Clin Lung Cancer; 2020 Sep; 21(5):e366-e379. PubMed ID: 32199806 [TBL] [Abstract][Full Text] [Related]
12. Consistency Analysis of Programmed Death Ligand 1 Expression in Non-Small Cell Lung Cancer Between Pleural Effusion and Matched Primary Lung Cancer Tissues by Immunohistochemical Double Staining. Sun Z; Xiao X; Liang S; Ma H; Sun Y; Zhao L; Wang C; Chang X; Zhao H; Guo H; Zhang Z Lab Invest; 2024 Jun; 104(6):102058. PubMed ID: 38626874 [TBL] [Abstract][Full Text] [Related]
13. Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion. Tamiya M; Tamiya A; Yasue T; Nakao K; Omachi N; Shiroyama T; Tani E; Hamaguchi M; Morishita N; Suzuki H; Okamoto N; Okishio K; Kawaguchi T; Atagi S; Hirashima T Anticancer Res; 2016 Jun; 36(6):2939-44. PubMed ID: 27272808 [TBL] [Abstract][Full Text] [Related]
14. Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody. Murakami S; Shibaki R; Matsumoto Y; Yoshida T; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Ohe Y Thorac Cancer; 2020 Dec; 11(12):3585-3595. PubMed ID: 33108686 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer. Imai H; Wasamoto S; Yamaguchi O; Suzuki K; Sugiyama T; Uchino J; Minemura H; Osaki T; Ishii H; Umeda Y; Mori K; Kotake M; Kagamu H; Morozumi N; Taniguchi H; Kasai T; Minato K; Kaira K J Cancer Res Clin Oncol; 2020 Feb; 146(2):457-466. PubMed ID: 31853661 [TBL] [Abstract][Full Text] [Related]
17. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer. Ito K; Miura S; Sakaguchi T; Murotani K; Horita N; Akamatsu H; Uemura K; Morita S; Yamamoto N Lung Cancer; 2019 Feb; 128():113-119. PubMed ID: 30642442 [TBL] [Abstract][Full Text] [Related]
18. Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy. Niemeijer AN; Sahba S; Smit EF; Lissenberg-Witte BI; de Langen AJ; Thunnissen E Br J Cancer; 2020 Aug; 123(3):392-402. PubMed ID: 32433601 [TBL] [Abstract][Full Text] [Related]
19. Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab. Morita M; Tamiya M; Fujimoto D; Tamiya A; Suzuki H; Hirano K; Fukuda Y; Yokoyama T; Kominami R; Kanazu M; Uchida J; Hara S; Yamashita S; Tomioka H BMC Cancer; 2020 Feb; 20(1):93. PubMed ID: 32013910 [TBL] [Abstract][Full Text] [Related]
20. A Multivariable Regression Model-based Nomogram for Estimating the Overall Survival of Patients Previously Treated With Nivolumab for Advanced Non-small-cell Lung Cancer. Tamiya A; Tamiya M; Go H; Inoue T; Kunimasa K; Nakahama K; Taniguchi Y; Shiroyama T; Isa SI; Nishino K; Kumagai T; Suzuki H; Hirashima T; Atagi S; Shintani A; Imamura F Anticancer Res; 2020 Aug; 40(8):4229-4236. PubMed ID: 32727749 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]